Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Suceagu – page 21

447 clinical trials in Suceagu, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Suceagu at a glance
447
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

447 trials in Suceagu

Open in trial search

Crohn's disease

Not recruiting

Study on Tulisokibart for Treating Moderate to Severe Crohn's Disease in Adults

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Study of cabozantinib with atezolizumab compared to sorafenib in untreated patients with advanced liver cancer (hepatocellular carcinoma)

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Exelixis Inc.

Hepatic cirrhosis

Not recruiting

Study on Zibotentan and Dapagliflozin for Patients with Liver Cirrhosis and Portal Hypertension

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:AstraZeneca AB

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.

Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Asthma

Not recruiting

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Chiesi Farmaceutici S.p.A.

Diabetes mellitus

Not recruiting

Bioequivalence Study of Dapagliflozin 10 mg Tablets in Healthy Adult Volunteers with Diabetes

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · Healthy volunteers
  • Substances:Dapagliflozin
  • Sponsor:Sun Pharmaceutical Industries Limited

Phase 3 Study of Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Metastatic NSCLC with PD-L1 TPS ≥50%

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Suceagu

What the registry says about research in the country

01 Female Urogenital Diseases and Pregnancy Complications

In Suceagu, clinical research in female urogenital diseases is focused on improving care for stress urinary incontinence. The trials are looking at whether new treatment approaches can better reduce symptoms and support daily comfort for women living with this condition.

  • Stress urinary incontinence
  • Female urogenital health
  • Symptom control and quality of life
  • Evaluating a new therapy approach

This area reflects a practical effort to find more effective options for a common and often disruptive condition.

02 Neoplasms

Cancer research in this city includes studies in non-small cell lung cancer, with attention on patients who have HER2 mutations. The work is aimed at determining whether a targeted treatment can improve outcomes compared with standard care after surgery.

  • Non-small cell lung cancer
  • HER2-mutated tumors
  • Post-surgical cancer care
  • Testing treatment effectiveness

This field highlights efforts to advance more precise cancer treatment strategies and strengthen long-term disease control.

03 Metabolic and Urologic Symptom Research

Another active focus combines obesity or overweight with urinary incontinence, reflecting interest in how weight-related health issues may affect urinary symptoms. The research is designed to see whether a new therapy can better improve patient-reported outcomes.

  • Obesity and overweight
  • Urinary incontinence
  • Women’s health
  • Improving symptom outcomes

These studies bring together metabolic and urologic care in a way that may help guide more personalized treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.